Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
NLR family CARD domain-containing protein 3 (NLRC3) is a cytosolic pattern recognition receptor in the NOD-like receptor family. NLRC3 contains a CARD domain, a nucleotide-binding (NBD) domain, and leucine-rich repeats (LRR), and is primarily expressed in immune cells. Unlike other NOD-like receptors that act as positive innate immune sensors, NLRC3 serves as a negative regulator, attenuating activation of NF-κB and STING pathways, suppressing inflammasome formation, and limiting cell proliferation. It prevents inflammasome assembly by interacting with ASC and pro-caspase-1, modulates T cell activation and differentiation, and negatively regulates the PI3K-AKT-mTOR pathway, thus controlling cell fate and immune responses. NLRC3 is implicated in a range of immune-mediated diseases, including infections, sterile inflammation, and cancer, largely through its roles in dampening immune responses and cell proliferation[1][2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on NLR family CARD domain-containing protein 3 (NLRC3).